| Asthma
Qvar RediHaler vs Rayos
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Qvar Redihaler vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Qvar Redihaler based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Qvar Redihaler, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qvar Redihaler
Rayos
At A Glance
Oral inhalation
Twice daily
Inhaled corticosteroid
Oral
Daily
Corticosteroid
Indications
- Asthma
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Asthma (adults and adolescents, >=12 years) 40 to 320 mcg twice daily by oral inhalation, approximately 12 hours apart; starting dose 40 to 80 mcg twice daily for those not on an inhaled corticosteroid; maximum 320 mcg twice daily.
Asthma (pediatric, 4 to 11 years) 40 mcg twice daily by oral inhalation, approximately 12 hours apart; may increase to 80 mcg twice daily after 2 weeks if needed; maximum 80 mcg twice daily.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures
- Known hypersensitivity to beclomethasone dipropionate or any ingredient in QVAR REDIHALER
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=3%) oral candidiasis, upper respiratory tract infection, nasopharyngitis, oropharyngeal pain, viral upper respiratory tract infection, sinusitis, pharyngitis, headache, pyrexia
Serious oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing localized Candida infections, aggression, depression, sleep disorders, psychomotor hyperactivity, suicidal ideation (primarily in children), blurred vision, central serous chorioretinopathy
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Inhaled corticosteroid prodrug; beclomethasone dipropionate is rapidly hydrolyzed to the active monoester 17-monopropionate (17-BMP), which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) to reduce airway inflammation in asthma.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qvar Redihaler
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (9/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Qvar Redihaler
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Qvar Redihaler
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qvar Redihaler.
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Qvar RedihalerView full Qvar Redihaler profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.